Pronova BioPharma ASA : Par and Teva have filed a notice of appeal
(Thomson Reuters ONE) -
Oslo, Norway, 26 June 2012: Pronova BioPharma (OSE: PRON.OL)
announced on 29 May 2012 that the U.S. District Court for the District of
Delaware ruled in Pronova's favour in the patent litigation involving U.S.
Patent Nos. 5,656,667 and 5,502,077 covering Lovaza(TM).
Today Pronova has been informed that both Par and Teva have filed the formal
Notice of Appeal of the decision rendered by the District Court of Delaware to
the United States Court of Appeals for the Federal Circuit.
Par and Teva have 60 days to submit the grounds of appeal and a ruling is
expected in the third quarter of 2013.
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pronova BioPharma ASA via Thomson Reuters ONE
[HUG#1622001]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.06.2012 - 03:37 Uhr
Sprache: Deutsch
News-ID 1127620
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Lysaker
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 119 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pronova BioPharma ASA : Par and Teva have filed a notice of appeal
"
steht unter der journalistisch-redaktionellen Verantwortung von
Pronova BioPharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
